| 39.7 0.15 (0.38%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 50.13 | 1-year : | 58.55 |
| Resists | First : | 42.91 | Second : | 50.13 |
| Pivot price | 39.23  |
|||
| Supports | First : | 36.86 | Second : | 33.12 |
| MAs | MA(5) : | 38.95 |
MA(20) : | 38.8 |
| MA(100) : | 36.54 |
MA(250) : | 25.69 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 61.5 |
D(3) : | 55.4 |
| RSI | RSI(14): 53.2 |
|||
| 52-week | High : | 57.13 | Low : | 6.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NBTX ] has closed below upper band by 41.8%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 40.14 - 40.33 | 40.33 - 40.51 |
| Low: | 38.74 - 38.96 | 38.96 - 39.17 |
| Close: | 39.34 - 39.68 | 39.68 - 40.01 |
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Fri, 24 Jul 2026
NBTX|Nanobiotix SA|Price:39.310|Chg%:-0.240 - TradingKey
Thu, 25 Jun 2026
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform (NASDAQ:NBTX) - Seeking Alpha
Mon, 22 Jun 2026
Nanobiotix (NBTX) Provides Update on Operational Progress - Yahoo Finance
Fri, 12 Jun 2026
Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech (NASDAQ:NBTX) - Seeking Alpha
Tue, 02 Jun 2026
Nanobiotix Provides First Quarter 2026 Operational and Financial Update - Yahoo Finance
Tue, 02 Jun 2026
Lung cancer trial shows responses in 6 of 7 patients on Nanobiotix drug - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 11.7 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 33 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2 |
| Profit Margin | -73.6 % |
| Operating Margin | -196.5 % |
| Return on Assets (ttm) | -10.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.64 |
| Sales Per Share | 0.64 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -68.45 |
| PEG Ratio | 0 |
| Price to Book value | -19.95 |
| Price to Sales | 61.87 |
| Price to Cash Flow | -60.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|